Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Bought by Systematic Financial Management LP

Systematic Financial Management LP increased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 40.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 860,563 shares of the life sciences company's stock after buying an additional 248,817 shares during the quarter. Systematic Financial Management LP owned about 1.12% of Integra LifeSciences worth $19,518,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC raised its position in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the period. Sterling Capital Management LLC raised its position in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after purchasing an additional 1,931 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the last quarter. Covestor Ltd grew its holdings in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth about $180,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Down 1.7%

NASDAQ:IART traded down $0.23 during trading hours on Tuesday, hitting $13.32. The company's stock had a trading volume of 1,107,185 shares, compared to its average volume of 1,047,739. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.04 billion, a P/E ratio of -147.98, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The stock has a fifty day moving average of $17.82 and a 200-day moving average of $21.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.55 earnings per share. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of research analyst reports. Wells Fargo & Company cut their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JMP Securities dropped their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.